Shan Liang
National Center for Biotechnology Information, NLM, NIH
The probe F-6-fluoro--[2-(diethylamino)ethyl]pyridine-3-carboxamide, abbreviated as F-MEL050, was synthesized by Denoyer et al. for use with melanin-targeted positron emission tomography (PET) of melanoma and its metastasis (1, 2). Melanoma is a highly malignant tumor that originates in melanocytes. The patient’s outcome is highly dependent on the early detection of metastasis and on the accuracy of staging. Currently, PET with 2-deoxy-2-[F]fluoro-d-glucose ([F]FDG) is routinely used for the staging of melanoma, especially for patients with visceral, deep soft tissue, and lymph node metastases (3). However, [F]FDG PET suffers from poor sensitivity for the assessment of early stage and small melanomas because of its dependence on glucose metabolism of tumor cells. Lack of specificity of [F]FDG also makes it difficult to discriminate lymph node metastasis and inflammatory lymphadenopathy (1, 2). In recent years, several other radiolabeled imaging probes have been evaluated for melanoma imaging by targeting melanoma-associated antigens, α-melanocyte–stimulating hormones, and melanin. Of these probes, benzamide (BZ) derivatives are one group of the most promising radiotracers for both diagnosis and therapeutic applications (4, 5). BZ derivatives represent a versatile class of aromatic compounds that exhibit high and specific binding with melanin in melanoma cells and melanocytes (6, 7). Clinical trials with the agents of [I]BZA and [I]BZA2 have demonstrated the high sensitivity and selectivity of these agents in the detection of melanoma and its metastasis (8-10). Because of the promising results, a large series of BZ derivatives are currently under investigation in animal models of melanoma. In general, these agents exhibit comparable properties, but they present different kinetic profiles Most BZ derivatives exhibit significant liver retention and a predominant clearance the hepatobiliary system, which potentially limits detection of abdominal lesions (1, 11). Denoyer et al. synthesized a series of fluoronicotinamide compounds (1, 2, 11). The enhanced hydrophilicity of the pyridine nitrogen allows for rapid clearance of the compounds renal excretion. The nicotinamide structure is amenable to direct nucleophilic substitution a rapid, one-step synthesis that provides a means for high-yield incorporation of the F into these molecules. These F-labeled compounds, including F-MEL050, exhibited high radiochemical stability, excellent tumor uptake, and favorable pharmacokinetic properties with excretion predominantly the renal route (1, 2, 11). These positive characteristics suggest that these agents are potentially valuable as PET agents for early detection of melanoma and its metastasis. This chapter summarizes the data obtained with F-MEL050 (1, 2).
探针F-6-氟--[2-(二乙氨基)乙基]吡啶-3-甲酰胺,简称为F-MEL050,由德诺耶等人合成,用于黑色素瘤及其转移灶的黑色素靶向正电子发射断层扫描(PET)(1,2)。黑色素瘤是一种起源于黑素细胞的高度恶性肿瘤。患者的预后高度依赖于转移灶的早期检测和分期的准确性。目前,2-脱氧-2-[F]氟-D-葡萄糖([F]FDG)PET常规用于黑色素瘤的分期,特别是对于有内脏、深部软组织和淋巴结转移的患者(3)。然而,[F]FDG PET对早期和小黑色素瘤的评估敏感性较差,因为它依赖于肿瘤细胞的葡萄糖代谢。[F]FDG缺乏特异性也使得难以区分淋巴结转移和炎性淋巴结病(1,2)。近年来,已经评估了其他几种放射性标记的成像探针,通过靶向黑色素瘤相关抗原、α-黑素细胞刺激激素和黑色素来进行黑色素瘤成像。在这些探针中,苯甲酰胺(BZ)衍生物是最有前途的用于诊断和治疗应用的放射性示踪剂之一(4,5)。BZ衍生物是一类通用的芳香族化合物,在黑色素瘤细胞和黑素细胞中与黑色素表现出高特异性结合(6,7)。[I]BZA和[I]BZA2制剂的临床试验已经证明了这些制剂在检测黑色素瘤及其转移灶方面的高敏感性和选择性(8-10)。由于结果令人鼓舞,目前正在黑色素瘤动物模型中对大量系列的BZ衍生物进行研究。一般来说,这些制剂表现出可比的性质,但它们呈现出不同的动力学特征。大多数BZ衍生物表现出显著的肝脏滞留和主要通过肝胆系统清除,这可能会限制对腹部病变的检测(1,11)。德诺耶等人合成了一系列氟代烟酰胺化合物(1,2,11)。吡啶氮的亲水性增强使得这些化合物能够通过肾脏排泄快速清除。烟酰胺结构适合直接亲核取代,这是一种快速的一步合成方法,为将F高产率地掺入这些分子中提供了一种手段。这些F标记的化合物,包括F-MEL050,表现出高放射化学稳定性、优异的肿瘤摄取以及主要通过肾脏途径排泄的良好药代动力学性质(1,2,11)。这些积极特征表明这些制剂作为PET制剂对于早期检测黑色素瘤及其转移灶可能具有重要价值。本章总结了用F-MEL050获得的数据(1,2)。